183 related articles for article (PubMed ID: 30790545)
1. MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins.
Moore LM; Cho S; Thoren KL
Clin Chim Acta; 2019 May; 492():91-94. PubMed ID: 30790545
[TBL] [Abstract][Full Text] [Related]
2. MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins.
Fatica EM; Martinez M; Ladwig PM; Murray JD; Kohlhagen MC; Kyle RA; Kourelis T; Lust JA; Snyder MR; Dispenzieri A; Murray DL; Willrich MAV
Clin Biochem; 2021 Nov; 97():67-73. PubMed ID: 34384797
[TBL] [Abstract][Full Text] [Related]
3. Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy.
Eveillard M; Korde N; Ciardiello A; Diamond B; Lesokhin A; Mailankody S; Smith E; Hassoun H; Hultcrantz M; Shah U; Lu S; Salcedo M; Werner K; Rispoli J; Mastey D; Landgren O; Thoren K
Clin Chim Acta; 2021 May; 516():136-141. PubMed ID: 33545108
[TBL] [Abstract][Full Text] [Related]
4. Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay.
Thoren KL; Pianko MJ; Maakaroun Y; Landgren CO; Ramanathan LV
J Appl Lab Med; 2019 Mar; 3(5):857-863. PubMed ID: 31639760
[TBL] [Abstract][Full Text] [Related]
5. Direct Detection of Monoclonal Free Light Chains in Serum by Use of Immunoenrichment-Coupled MALDI-TOF Mass Spectrometry.
Sepiashvili L; Kohlhagen MC; Snyder MR; Willrich MAV; Mills JR; Dispenzieri A; Murray DL
Clin Chem; 2019 Aug; 65(8):1015-1022. PubMed ID: 31171529
[TBL] [Abstract][Full Text] [Related]
6. Detection of serum M-protein in acetonitrile precipitates by MALDI-TOF mass spectrometry: A novel, low-cost methodology.
Mehra N; Gopisetty G; Subramani J; Dhanasekar S; Rajamanickam A; Perumal Kalaiyarasi J; Karunakaran P; Kannan K; Rajaraman S; Rajkumar T
Ann Clin Biochem; 2023 Sep; 60(5):339-348. PubMed ID: 37158306
[TBL] [Abstract][Full Text] [Related]
7. Clearing drug interferences in myeloma treatment using mass spectrometry.
Kohlhagen MC; Mills JR; Willrich MAV; Dasari S; Dispenzieri A; Murray DL
Clin Biochem; 2021 Jun; 92():61-66. PubMed ID: 33691184
[TBL] [Abstract][Full Text] [Related]
8. Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference.
Noori S; Verkleij CPM; Zajec M; Langerhorst P; Bosman PWC; de Rijke YB; Zweegman S; VanDuijn M; Luider T; van de Donk NWCJ; Jacobs JFM
Clin Chem Lab Med; 2021 Nov; 59(12):1963-1971. PubMed ID: 34392637
[TBL] [Abstract][Full Text] [Related]
9. Mitigating the interference of Daratumumab with immunofixation electrophoresis. A single-center experience using Hydrashift 2/4 kit.
Duek A; Lellouche E; Ben Baruch S; Mashiach R; Segman Y; Bryk G; Leiba M
Isr Med Assoc J; 2022 Oct; 24(10):629-633. PubMed ID: 36309856
[TBL] [Abstract][Full Text] [Related]
10. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
McCudden C; Axel AE; Slaets D; Dejoie T; Clemens PL; Frans S; Bald J; Plesner T; Jacobs JF; van de Donk NW; Moreau P; Schecter JM; Ahmadi T; Sasser AK
Clin Chem Lab Med; 2016 Jun; 54(6):1095-104. PubMed ID: 27028734
[TBL] [Abstract][Full Text] [Related]
11. [Application of Hydrashift 2/4 daratumumab assay in eliminating interference of daratumumab on serum immunofixation electrophoresis].
Xu S; Liu Y; Wen L; Zhao L; Deng X; Rong R; Lu J
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):840-845. PubMed ID: 34788924
[No Abstract] [Full Text] [Related]
12. Using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry to detect monoclonal immunoglobulin light chains in serum and urine.
Barnidge DR; Krick TP; Griffin TJ; Murray DL
Rapid Commun Mass Spectrom; 2015 Nov; 29(21):2057-60. PubMed ID: 26443406
[TBL] [Abstract][Full Text] [Related]
13. Identification of gamma heavy chain disease using MALDI-TOF mass spectrometry.
Thoren KL; Eveillard M; Chan P; Doddi S; Cho S; Murata K
Clin Biochem; 2020 Mar; 77():57-61. PubMed ID: 31884198
[TBL] [Abstract][Full Text] [Related]
14. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).
van de Donk NW; Otten HG; El Haddad O; Axel A; Sasser AK; Croockewit S; Jacobs JF
Clin Chem Lab Med; 2016 Jun; 54(6):1105-9. PubMed ID: 26812873
[TBL] [Abstract][Full Text] [Related]
15. Use of MALDI-TOF mass spectrometry fingerprinting to characterize Enterococcus spp. and Escherichia coli isolates.
Santos T; Capelo JL; Santos HM; Oliveira I; Marinho C; Gonçalves A; Araújo JE; Poeta P; Igrejas G
J Proteomics; 2015 Sep; 127(Pt B):321-31. PubMed ID: 25753124
[TBL] [Abstract][Full Text] [Related]
16. Use of a Daratumumab-Specific Immunofixation Assay to Assess Possible Immunotherapy Interference at a Major Cancer Center: Our Experience and Recommendations.
Kirchhoff DC; Murata K; Thoren KL
J Appl Lab Med; 2021 Nov; 6(6):1476-1483. PubMed ID: 34293131
[TBL] [Abstract][Full Text] [Related]
17. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report.
Murray DL; Puig N; Kristinsson S; Usmani SZ; Dispenzieri A; Bianchi G; Kumar S; Chng WJ; Hajek R; Paiva B; Waage A; Rajkumar SV; Durie B
Blood Cancer J; 2021 Feb; 11(2):24. PubMed ID: 33563895
[TBL] [Abstract][Full Text] [Related]
18. Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab.
Kohlhagen M; Dasari S; Willrich M; Hetrick M; Netzel B; Dispenzieri A; Murray DL
Clin Chem Lab Med; 2020 Aug; 59(1):155-163. PubMed ID: 32745067
[TBL] [Abstract][Full Text] [Related]
19. Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.
Eveillard M; Rustad E; Roshal M; Zhang Y; Ciardiello A; Korde N; Hultcrantz M; Lu S; Shah U; Hassoun H; Smith E; Lesokhin A; Mailankody S; Landgren O; Thoren K
Br J Haematol; 2020 Jun; 189(5):904-907. PubMed ID: 32026474
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of glycation and glycation sites of lysozyme by matrix-assisted laser desorption/ionization time of flight/time-of-flight mass spectrometry and Liquid chromatography-electrospray ionization tandem mass spectrometry.
Ruan ED; Wang H; Ruan Y; Juáreza M
Eur J Mass Spectrom (Chichester); 2014; 20(4):327-36. PubMed ID: 25420345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
